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Summary
In Argentina, more than 3 million people suffer from asthma, with numbers
rising. When asthma patients acquire viral infections which, in turn, trigger
the asthmatic response, they may develop subsequent bacterial infections,
mainly by Streptococcus (S.) pneumoniae. This encapsulated Gram+ bacte-
rium has been considered historically a T cell-independent antigen. Never-
theless, several papers describe the role of T cells in the immune response to
S. pneumoniae. We evaluated the response to S. pneumoniae and compared it
to the response to Mycobacterium (M.) tuberculosis, a different type of bacte-
rium that requires a T helper type 1 (Th1) response, in cells from atopic asth-
matic children, to compare parameters for the same individual under
exacerbation and in a stable situation whenever possible. We studied asthma
patients and a control group of age-matched children, evaluating cell popula-
tions, activation markers and cytokine production by flow cytometry, and
cytokine concentration in serum and cell culture supernatants by enzyme-
linked immunosorbent assay (ELISA). No differences were observed in gd T
cells for the same patient in either situation, and a tendency to lower percent-
ages of CD4+CD25hi T cells was observed under stability.
A significantly lower production of tumour necrosis factor (TNF)-a and a
significantly higher production of interleukin (IL)-5 was observed in asthma
patients compared to healthy individuals, but no differences could be
observed for IL-4, IL-13 or IL-10. A greater early activation response against
M. tuberculosis, compared to S. pneumoniae, was observed in the asthmatic
patients’ cells. This may contribute to explaining why these patients fre-
quently acquire infections caused by the latter bacterium and not the former.
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Introduction
In Argentina more than 3 million people suffer from
asthma, and the number is rising. This is also true for many
other countries [1]. Asthma is a complex and heterogeneous
disease characterized by chronic airway inflammation and
airway hyperreactivity. This inflammatory pathology is
characterized by oedema and mucosal hyperaemia with
infiltration by mast cells, an overabundance of eosinophils
and activated T helper lymphocytes [2,3]. These inflamma-
tory cells release mediators that trigger bronchoconstric-
tion, mucus secretion and airway remodelling. The
inflammatory mediators that drive this process include
cytokines, chemokines, growth factors, lipid mediators,
immunoglobulins and histamine. In asthma, inflammation
is generally directed by T helper type 2 (Th2) cytokines,
which can act by positive feedback mechanisms to promote
the production of more inflammatory mediators, including
other cytokines and chemokines [4,5].
The chronic airway inflammation present in asthma
patients may contribute to impaired immunity and predis-
pose to infections that are more severe and long-lasting
than in healthy individuals [6–8]. These infections, often
caused by a virus, then trigger the asthmatic response,
which involves inflammation and which may elicit subse-
quent bacterial infections, most frequently by Streptococcus
(S.) pneumoniae or pneumococcus [9]. This may be due to
the fact that, in asthma patients, S. pneumoniae colonization
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is higher than in healthy controls. This, associated with
inflammatory stimuli that alter endothelium permeability,
would favour the development of lung infection, generating
pneumonia. Talbot et al. have described that asthma
patients have double the risk of invasive pneumococcal
disease than healthy individuals. In asthma airway remodel-
ling, on one hand, and increased mucin production as well
as altered secreted mucus, on the other hand, result in
impaired clearance of pathogenic bacteria of the airway,
generating the presence of debris that may harbour infec-
tious agents and contribute to the increased risk of pneu-
mococcus invasive infection [6].
S. pneumoniae is an encapsulated Gram+ bacterium
saprophyte of the high airways [10]. Host defence against
S. pneumoniae involves mainly acute phase responses and
antibodies against surface proteins, as well as against
polysaccharides. This pathogen has always been considered
a T cell-independent antigen, but a number of papers
describe the role of T cells in the immune response to
S. pneumoniae [11–14]. The immunoglobulin (Ig)G-
specific antibody response to this bacterium depends upon
CD4 T cells, B7/CD28 co-stimulation and the interaction
of CD40 with its ligand, while the IgM response is
T-independent [4]. It has been observed that T lym-
phocytes are involved in the early stages of the host
immune response to pneumococcal infection [15]. Other
studies have described that the T help required for induc-
tion of an antigen- specific humoral response in vivo
depends upon the type of pneumococcal antigen [5].
Snapper et al. [14] have studied many aspects of the
immune response to S. pneumoniae. They have demon-
strated recently in a murine model that Toll-like receptor
(TLR)-2 expression by B and CD4 T cells is critical for
induction of the T cell-dependent humoral immune
response to intact pneumococci [13]. Evidence is also accu-
mulating that the Th1 response is important for elimina-
tion of this pathogen, as interleukin (IL)-12-deficient
patients develop serious pneumococcal infections, and
interferon (IFN)-g has also been involved in the defence
against this pathogen [12]. Recently, the involvement of
Th1 and Th17 cells in the response to S. pneumoniae has
been reported [16].
Asthmatic patients are not more susceptible than healthy
individuals to other bacterial respiratory infections such as
tuberculosis. Therefore, we undertook to analyse if an
ongoing Th2 response, such as that present in atopic asth-
matic children, could modulate the response to S. pneumo-
niae and compare it to the response to Mycobacterium (M.)
tuberculosis, a different type of bacterium that requires a
Th1 response. Considering that asthma patients undergo
periods of exacerbation of their symptoms, triggered by
several stimuli, we were interested in determining whether
or not, in that situation, they had the same or a different




We recruited patients aged 7–18 years who met the asthma
diagnostic criteria. They were selected by high IgE levels, a
history of bronchial hyperreactivity, more than two bron-
chospasm crises per year and positive for cutaneous tests to
different allergens. We studied a total of 41 mild asthma
patients who had received bacilli Calmette–Guérin (BCG)
vaccination early in life and were on maintenance treatment
of inhaled fluticasone  250 mg/day. Samples were obtained
during either the remission period or stable condition
(n = 39) and, in some cases, at exacerbation (n = 19). In the
latter situation samples were taken from the patients before
the onset of oral corticosteroid treatment, provided to
relieve the symptoms of exacerbation. We compared the
whole group of patients in stable condition to a control
group. Then, for 17 patients, we compared the same param-
eter in the stable condition and undergoing exacerbation of
their symptoms, prior to rescue medication.
The control group consisted of age-matched healthy
children (aged 7–20 years), non-asthmatic, non-atopic,
undergoing routine blood tests prior to surgery (healthy
individuals) (n = 17), who had also received BCG vaccina-
tion early in life. In Argentina the conjugate pneumococcal
vaccine was incorporated into the National Vaccination Cal-
endar during the second semester of 2011 for children up
to 2 years of age. Hence, none of the individuals included
into this study had received any pneumococcal vaccine.
Informed consent was obtained for sample extraction as
well as inclusion into the study, which was approved by the
Ethics Committee of the Gutiérrez Children Hospital and
the Ethics Committee of the Institutes of the Academia
Nacional de Medicina.
Antigens
American Type Culture Collection (ATCC) 49619 S. pneu-
moniae (Spn), cultured, washed and heat-inactivated, was
kindly provided by the central Bacteriology Laboratory of
the National Institute of Infectious Diseases ANLIS Dr
Malbrán, and H37-RV M. tuberculosis (Mtb), cultured,
washed and heat-inactivated was kindly provided by the
Mycobacteria Service of the same institution. The correct
antigen concentration used was determined at the begin-
ning of the study by a dose–response curve.
Cell purification
Heparinized blood was collected and peripheral blood
mononuclear cells (PBMC) were isolated by Ficoll-Hypaque
gradient centrifugation. Cells were collected from the
interphase and resuspended in RPMI-1640 tissue cul-
ture medium (Gibco Laboratory, Grand Island, NY,
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USA) containing gentamycin (85 mg/ml) and 15% heat-
inactivated fetal calf serum (Gibco) (complete medium).
Cell culture
PBMC were cultured at 1 ¥ 106 cells/ml in 1 ml of complete
medium in Falcon 2003 tubes, at 37°C in a humidified 5%
CO2 atmosphere, in the presence or absence of 0·1 UDO/ml
of either Spn (2 ¥ 106 bacteria/ml) or Mtb (3 ¥ 106 bacteria/
ml) for different time-periods. Due to the small sample size,
the same culture was used both for activation marker evalu-
ation by flow cytometry and collection of supernatants, and
the 48-h time-point (t = 48) was chosen as a compromise to
obtain peak levels of cytokines and measurable levels of
both activation markers.
Cell populations and subpopulations
Eosinophils, basophils and B cells expressing bright IgE
were evaluated by flow cytometry on the day of sample
collection (t = 0) in whole blood by the use of anti-
CD45 phycoerythrin-cyanin 5 (PE-Cy5) (BD Pharmingen,
San Diego, CA, USA), anti-CD19 fluorescein isothiocyanate
(FITC) (Cytognos, Salamanca, Spain) and biotinylated anti-
IgE (Vector, Ontario, Canada), followed by streptavidin-PE
(Vector). Basophils were defined as CD19–CD45+IgE+ cells.
Populations expressing CD3, CD4, CD8, CD25, CD69
and TCR gd were also evaluated in PBMC by flow cytom-
etry using anti-CD3 PE-Cy5 (BD Pharmingen), anti-CD4
PE (BD Pharmingen), anti-CD8 FITC (Caltag Laboratories
Burlingame, CA, USA), anti-CD25 FITC (BD Pharmingen),
anti-CD69 PE (BD Pharmingen) and anti-TCR gd FITC
(BD Biosciences, Franklin Lakes, NJ, USA).
Cytokine evaluation
Intracellular cytokines were evaluated by flow cytometry in
whole blood cells from patients and healthy individuals.
Cells were stimulated with phorbol myristate acetate (PMA)
(50 ng/ml)/ionomycin (1 mM) in the presence of GolgiPlug
(BD Biosciences) for 5 h and then stained with membrane
anti-CD3 PE-Cy5 and anti-CD8 FITC. After fixation and
permeabilization using the Fix & Perm kit (Caltag Labora-
tories), cells were stained with intracellular PE-conjugated
antibodies for several cytokines: tumour necrosis factor
(TNF)-a (Caltag Laboratories), IL-4 (BD FastImmune),
IL-5 (BD Pharmingen), IL-13 (BD FastImmune), IFN-g
(Caltag Laboratories) and IL-10 (BD Pharmingen).
Cytokine production by PBMC was evaluated by com-
mercial enzyme-linked immunosorbent assay (ELISA) kits
(eBioscience, San Jose, CA, USA). The IL-5, IFN-g and IL-10
concentrations were measured in supernatants of PBMC
cultured for 48 h, with or without stimulation with Spn and
Mtb. In order to evaluate spontaneous production, cytokine
concentrations were measured in serum; we also evaluated
the presence of IgE with the UBI Magiwell ELISA kit
(United Biotech Inc., Mountain View, CA, USA).
Statistical analysis
GraphPad Prism version 5·0 was used for statistical analysis.
Statistical significance between parameters, measured in
healthy individuals and asthma patients at the time of the
sample extraction (t = 0), was determined by the Mann–
Whitney U-test. To compare the response to the same
stimulus (Spn or Mtb) in healthy individuals and asthma
patients, we used the Mann–Whitney U-test. The same
treatment of the data was performed to compare asthma
patients in stable versus exacerbation periods, but statistical
significance was determined by the Wilcoxon signed-rank
test, given that we studied the same asthma patients in both
conditions. To compare the different culture conditions
within a specific group (t = 48), statistical significance was
determined by a repeated-measures one-way analysis of




Taking into account that recent reports have described the
participation of T cells in acquired immunity to S. pneumo-
niae [10,13,16], showing that clearance of S. pneumoniae
depends upon CD4+ T cells in colonization studies, and
considering that this may also be true for mucosal disease
[10], we decided to study some T cell parameters.
We evaluated T cell subpopulations comparing healthy
individuals to asthma patients. In particular, we studied gd
T cells, as these have been implicated as important players
in the response to M. tuberculosis [17] and, to a lesser
degree, to S. pneumoniae [18]. As shown in Table 1a, gd T
cell percentages are significantly lower in asthma patients
than in healthy individuals. Comparison of cells from the
same patient in both stable and exacerbation conditions are
shown in Table 1b; no differences were observed in gd T
cells for the same patient in both conditions.
It has been suggested that CD4+CD25hi T cells may be
involved in regulating the development of allergies and
asthma [19,20]; therefore, we decided to evaluate
CD4+CD25hi T cells in our patients. As shown in Table 1a,
no difference in the percentages of CD4+CD25hi T cells was
observed in asthma patients compared to healthy individu-
als. When patients were compared in both exacerbation and
stable conditions, a tendency towards lower percentages of
CD4+CD25hi T cells could be observed in the latter
(Table 1b).
Activation markers
Expression of the CD69 and CD25 activation markers was
also evaluated in these ex-vivo-obtained T cells. As shown in
C. Otero et al.
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Table 1a, no significant differences could be observed in the
expression of these markers when healthy individuals were
compared to asthma patients. Similarly, no significant dif-
ferences were observed for the same patient in the stable or
exacerbation conditions (Table 1b).
Peripheral blood B cells and other
leucocyte populations
We then evaluated basophils, eosinophils and B cells
expressing IgE (IgE+ B cells), all of which are involved in
asthma. The data are shown in Table 2. No difference was
observed in basophil percentages when asthma patients
were compared to healthy individuals. Significantly higher
percentages of eosinophils were present in asthma patients.
IgE+ B cells were also increased significantly in asthma
patients. A significantly higher level of IgE was observed in
the sera of asthma patients compared to that of healthy
individuals, both in the stable and exacerbation conditions
(Table 3). No significant differences were observed for the
two patient conditions.
T cell activation
In order to evaluate the T cell response to the bacteria, we
cultured PBMC for 48 h in the presence or absence of Spn
or Mtb and then evaluated CD69 and CD25 activation
markers.
As shown in Fig. 1a,b, a significant difference can be
observed in cells from patients as well as from healthy indi-
viduals in the expression of CD69 in response to both bac-
terial antigens when compared to non-stimulated culture.
Expression of CD69 was significantly higher in cells from
asthma patients stimulated with Mtb with respect to
Spn. A significant difference was observed in response to
Mtb when compared to the response to Spn in asthma
patients, which cannot be seen in cells from healthy indi-
viduals. This appears to be due to a lower response to pneu-
mococci in the cells from asthma patients. When the same
patient was evaluated in both the stable and exacerbation
conditions, significant differences were observed in
response to the bacterial antigens compared to non-
stimulated cells (data not shown), but no differences were
found between the two patient conditions (Fig. 2a,b).
Expression of CD69 by stimulated gd T cells was signifi-
cantly different when compared to control for each bacterial
stimulus, but no differences were observed in healthy indi-
viduals by stimulation with Spn and Mtb (Fig. 1c). In
asthma patients, expression of CD69 was significantly
higher when stimulated with Mtb with respect to control
cells or those stimulated with Spn (Fig. 1d). CD69 expres-
sion was not increased significantly with Spn when com-
pared to control.
As shown in Fig. 3, CD25 expression was increased sig-
nificantly both in healthy individuals and asthma patients
when stimulated with Mtb, but not with Spn, for CD3 as
well as CD4 lymphocytes. Some authors have described a
role for CD8+ T cells in the antibody response to pneumo-
coccal polysaccharides [21]. In our study, the CD8 sub-
population showed an increase in CD25 expression only
with Mtb in cells from asthma patients, not in cells from
healthy individuals. When the expression was compared in
both the stable and exacerbation conditions for the same
patient, no significant differences could be detected in
response to the same bacterial antigen. Only the percentage
of CD3+CD25+ T cells from asthma patients in the stable
condition is significantly higher than in the exacerbation
period (Fig. 4). This may be due to the migration of acti-
vated cells to the inflammation site during asthmatic
exacerbation.
Table 1. T cell subsets in healthy and asthmatic individuals.
(a)
t = 0 Healthy individuals Asthma patients
% T cells
CD3+ 68·90  4·35 63·69  3·35
CD3+ gd 7·85  1·40 4·00  0·44*
CD3+ CD69+ gd 9·86  3·00 7·05  1·68
CD3+ CD69+ 2·95  0·60 2·61  0·28
CD3+ CD25+ 7·38  2·00 8·43  0·80
CD4+ CD25+ 6·31  1·72 7·24  0·87
CD8+ CD25+ 1·01  0·36 0·63  0·08






CD3+ gd 2·96  0·41 3·11  0·46
CD3+CD69+ gd 5·20  0·95 6·61  1·19
CD3+CD69+ 2·51  0·36 2·18  0·45
CD3+CD25+ 8·40  0·96 7·60  1·24
CD4+ CD25+ 7·50  1·11 7·65  4·50
CD8+ CD25+ 0·64  0·11 0·88  0·19
CD4+CD25hi 1·27  0·41 1·64  0·40
(a) Percentage of T cell subsets analysed ex vivo (t = 0), from
healthy individuals versus asthma patients. Significance: *P < 0·05 by
Mann–Whitney U-test. (b) Percentage of T cell subsets analysed ex vivo
(t = 0), from asthma patients during the stable condition versus exacer-
bation. No significant differences were found by Wilcoxon’s signed-
rank test.
Table 2. Peripheral blood B cells and other leucocyte populations in
healthy and asthmatic individuals.
t = 0 Healthy individuals Asthma patients
% Basophils 0·91  0·17 0·76  0·11
% Eosinophils 2·47  0·17 6·39  0·61***
% IgE+ B cells 4·55  0·92 6·55  0·71*
Percentage of basophils, eosinophils and immunoglobulin (Ig)E+ B
cells, analysed ex vivo (t = 0), from both healthy individuals and asthma
patients. Significance: *P < 0·05; ***P < 0·0001 by Mann–Whitney
U-test.
Immune response to Streptococcus pneumoniae in asthma patients
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Cytokine production
We first evaluated the cytokine production capacity of T
cells by non-specific stimulation and flow cytometry in
whole blood cells from asthmatic patients in the stable con-
dition and in healthy individuals. Data are presented in
Table 4. Significantly lower production of TNF-a was
observed in asthma patients compared to healthy
Table 3. Serum soluble immune factors in healthy and asthmatic individuals.
Blood serum (t = 0) Healthy individuals
Asthma patients
Stability Exacerbation
IFN-g (pg/ml) > 500 (n = 9) 118·30  51·94 (n = 7) 85·31  41·05 (n = 6)
IL-5 (pg/ml) < 3·9 (n = 9) 80·19  41·41 (n = 7) 66·31  29·09 (n = 9)
IL-10 (pg/ml) 12·70  3·56 (n = 10) 22·46  7·00 (n = 11) 23·10  7·16 (n = 11)
IgE (IU/ml) 60·15  11·96 (n = 11) 1262·00  304·80 (n = 13)** 1545·00  319·90 (n = 11)***
Concentration of interferon (IFN)-g, interleukin (IL)-5, IL-10 and immunoglobulin (Ig)E in serum samples from healthy individuals and asthma






























































































Fig. 1. CD69 expression induced by bacterial
antigens in T cells. Percentage of CD3+CD69+ T
cells and CD3+CD69+ gd T cells from healthy
individuals (a,c) and asthma patients (b,d),
respectively, after stimulation in culture
with Streptococcus pneumoniae (Spn),
Mycobacterium tuberculosis (Mtb) or without
stimulus (control). Significance: *P < 0·05;
**P < 0·001; ***P < 0·0001 (versus control);
###P < 0·0001 (versus Spn); by one-way analysis




















































































Fig. 2. CD69 expression induced by bacterial
antigens in T cells from asthma patients in the
stable condition and in exacerbation. Percentage
of CD3+CD69+ T cells and CD3+CD69+ gd T
cells, from the same asthma patients in both
conditions, after stimulation in culture
with Streptococcus pneumoniae (a,c) or
Mycobacterium tuberculosis (b,d). No significant
differences were found by Wilcoxon’s
signed-rank test.
C. Otero et al.















































































































Fig. 3. CD25 expression induced by bacterial
antigens in T cells. Percentage of CD3+CD25+ T
cells, CD4+CD25+ T cells and CD8+CD25+ T
cells from healthy individuals (a,c,e) and
asthma patients (b,d,f), respectively,
after stimulation in culture with Streptococcus
pneumoniae (Spn), Mycobacterium tuberculosis
(Mtb) or without stimulus (control).
Significance: *P < 0·05 and ***P < 0·0001 (versus
control); ###P < 0·0001 (versus Spn); by one-way
analysis of variance (anova), with Tukey’s


































































































Fig. 4. CD25 expression induced by bacterial
antigens in T cells from asthma patients in
stable condition and in exacerbation. The
percentage of CD3+CD25+ T cells, CD4+CD25+
T cells and CD8+CD25+ T cells, from the
same asthma patients in both conditions,
after stimulation in culture with Streptococcus
pneumoniae (a,c,e) or Mycobacterium
tuberculosis (b,d,f). Significance: *P < 0·05; by
Wilcoxon’s signed-rank test.
Immune response to Streptococcus pneumoniae in asthma patients
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individuals. A marked tendency to lower production of
IFN-g, a Th1 cytokine, although non-significant, was also
observed in the cells from asthma patients.
In contrast, a significantly higher production of IL-5, a
characteristic Th2 cytokine, was observed in these patients,
but no differences could be observed for IL-4 and IL-13,
hallmarks of asthma and other allergic conditions, or for
IL-10, a regulatory cytokine.
In order to gain insight into the cytokine environment to
which the peripheral blood cells were exposed in vivo, the
concentration of some cytokines was also determined in
blood serum. The results presented in Table 3 demonstrate
that serum IFN-g was lower and IL-5 higher in asthma
patients compared to healthy individuals, while no signifi-
cant differences were evident for IL-10.
As a second measure of T cell activation, using ELISA we
also evaluated cytokine production in response to bacterial
antigens by culturing PBMC in the presence or absence of
Spn or Mtb. Cytokines representative of three T cell sub-
populations (Th1, Th2 and regulatory) were evaluated in
patients in the stable condition and at exacerbation of their
symptoms (Table 5). The concentration of IFN-g was above
detection limit in the cells from asthma patients in exacer-
bation, even with no stimulus. For healthy individuals and
patients in the stable condition, that type of concentration
was reached by stimulation with either one of the bacteria.
Nevertheless, a tendency to lower levels of the Th2 cytokine
IL-5 were observed under exacerbation with respect to the
stable condition, but differences were non-significant.
Finally, IL-10 was evaluated as a cytokine produced by
regulatory cells. IL-10 production was stimulated greatly by
both Spn and Mtb when compared to non-stimulated cul-
tured cells. Its level was not significantly different with both
bacterial stimuli and in both patient conditions.
Discussion
Asthma patients suffer acute exacerbation of their symp-
toms triggered by several stimuli, associated with an
increase of airway inflammation, increased levels of inflam-
Table 4. Cytokine production capacity of T cells by non-specific stimulation.
Whole blood cultures Healthy individuals Asthma patients
% T cells
CD3+ TNF-a+ 28·52  5·70 (n = 13) 6·78  2·73 (n = 10)**
CD3+ IFN-g+ 15·99  3·09 (n = 13) 8·59  3·71 (n = 10)
CD3+ IL-4+ 0·41  0·11 (n = 10) 0·39  0·18 (n = 10)
CD3+ IL-5+ 0·31  0·04 (n = 12) 1·78  0·73 (n = 10)*
CD3+ IL-13+ 0·62  0·22 (n = 13) 0·60  0·27 (n = 5)
CD3+ IL-10+ 0·19  0·05 (n = 12) 0·17  0·05 (n = 8)
Percentage of CD3+ T cells expressing tumour necrosis factor (TNF)-a, interferon (IFN)-g, interleukin (IL)-4, IL-5, IL-13 or IL-10 after stimula-
tion of whole blood cells with phorbol myristate acetate (PMA)/ionomycin for 5 h, from both healthy individuals and asthma patients. Significance:
**P < 0·001; *P < 0·05 by Mann–Whitney U-test.





n = 3 n = 7 n = 5
Control w/o bacteria 96·10  60·10 79·20  51·6 > 500
Streptococcus pneumoniae > 500 > 500 > 500
Mycobacterium tuberculosis > 500 > 500 > 500
IL-5 (pg/ml)
n = 3 n = 7 n = 5
Control w/o bacteria < 3·9 < 3·9 2·22  2·22
S. pneumoniae < 3·9 6·50  4·30 4·20  2·60
M. tuberculosis < 3·9 25·90  17·00 14·30  9·40
IL-10 (pg/ml)
n = 8 n = 7 n = 5
Control w/o bacteria 16·67  6·42 20·58  4·10 17·34  6·46
S. pneumoniae 181·20  55·31 169·80  49·21 174·60  27·54
M. tuberculosis 102·20  24·13 140·80  41·57 187·20  39·64
Concentration of interferon (IFN)-g, interleukin (IL)-5 and IL-10 in supernatants obtained after 48 h stimulation in culture with S. pneumoniae,
M. tuberculosis or without stimulus (control). Data correspond to healthy individuals and asthma patients during both the stable condition and exac-
erbation. No significant differences were found by Mann–Whitney U-test.
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matory factors and higher numbers of infiltrating cells. This
represents a severe burden on the health-care system,
accounting for approximately 50% of the costs linked to
asthma, but it also affects the patient’s quality of life [22].
Nevertheless, most of the time asthma patients are in the
stable condition, with absence of asthma symptoms and
normal peak expiratory flow (PEF) and forced expiratory
volume in 1 s (FEV1) [23]. Viral infections are one of the
most common causes of exacerbations of asthma [24] and,
they may open the way for bacterial infections, and S. pneu-
moniae is frequently involved in respiratory infections asso-
ciated with wheezing [25].
Recent evidence suggests that allergic asthma is a multi-
faceted condition controlled actively by effector as well as
regulatory T cells (Tregs). Effector cells increase airway
inflammation, while Tregs are anti-inflammatory. Cytokines
are involved in the development and activation of all T cell
subpopulations [20]. They are also involved directly or indi-
rectly in most approaches to asthma treatment.
The classical view considers the immune response to
S. pneumoniae to be based on anti-capsular antibodies, but
several reports have described the involvement of T cells
[10,16,20]. Mureithi et al. have demonstrated the presence
of T cell memory in response to this pathogen in human
PBMC [26]. Recently, Olliver et al. have characterized the
immune response to this pathogen in humans [16], while
several reports have described T cell involvement in the
immune response to S. pneumoniae in animal models
[27,28].
Kirby et al. have reported evidence for the involvement of
lung-specific gd T cell subsets in local responses to S. pneu-
moniae infection [18]. This T cell subset is considered
important in the immune response to M. tuberculosis [29].
The lower percentage of gd T cells that we observed in
asthma patients would affect the immune response to Spn
as well as to Mtb. It may therefore be detrimental in both
cases, but this would not explain a differential susceptibility
to infection with these agents.
Some authors have described a role for CD8+ T cells in
the immune response to pneumococcus [21,30]. In our
experiments, the CD8 subpopulation showed an increase in
CD25 expression only with Mtb in cells from asthma
patients, and not in cells from healthy individuals. This acti-
vation may also be a contributory factor in the defence
against Mtb, and not to Spn, although the overall immune
response will depend upon the balance of all the T cell
subpopulations.
An important role has been ascribed to Treg cells in the
development of atopic asthma. Several authors have sug-
gested that Treg cell deficiency could be the cause of allergies
and atopic asthma. Some authors have reported lower levels
of Treg cells in asthma patients [31]. Pumputiene et al. have
recently studied CD4+CD25hi regulatory cells in atopic
asthmatic children, both during remission and exacerba-
tion [32]. They observed no significant correlation of
CD4+CD25hi T cell percentages. They also report no reduc-
tion in peripheral blood Treg cells compared to controls.
This is in accordance with our data, with no statistical dif-
ferences in the proportion of this T cell subpopulation in
either condition of the patients and in healthy individuals.
We also agree with this group, in that if one could study
cells from the local tissue, differences both in numbers and
function might be observed.
T cells are well characterized with respect to their func-
tion in protective humoral immune responses; however,
their roles during early stages of infection and invasive
pneumococcal disease are less well defined. Using a mouse
model of pneumococcal sepsis, LeMessurier et al. found
that CD4+ T cells were recruited to the lung as early as 12 h
after intranasal infection. Recruitment was accompanied by
up-regulation of CD69 and B7-H1, reflecting T cell activa-
tion. They suggest an important and adverse role of CD4+ T
cells in the pathogenesis of invasive pneumococcal disease
[33].
The immune response to an antigen can be evaluated by
the expression of activation markers on lymphocytes as well
as cytokine production after stimulation of PBMC with the
antigen. CD69 is an early activation marker of lymphocytes.
In a recent report, Martin et al. proposed that CD69 expres-
sion can modulate T lymphocyte differentiation towards
the Th17 lineage in allergic asthma and other inflammatory
diseases. CD69 promotes activation of the Jak3-signal trans-
ducer and activator of transcription 5 (STAT-5) signalling
pathway, which inhibits Th17 cell differentiation, thus pro-
viding a mechanistic link between CD69 and the regulation
of Th17 responses [34]. Th17 cells have been described in
turn as relevant in the immune response to S. pneumoniae
[10]. Other authors have reported that CD69 plays a crucial
role in the pathogenesis of allergen-induced eosinophilic
airway inflammation and hyperresponsiveness [35]. Taking
all this information into consideration, the expression of
CD69 was evaluated. A greater early activation response
against Mtb, compared to Spn, was observed in the cells
from asthma patients. This difference in CD69 expression
was not observed in the cells from healthy individuals. A
deficient early activation in response to Spn in the cells
from asthmatic individuals, which would also impair the
subsequent T helper effector response, may help to explain
the different frequencies of infection with these two patho-
gens reported in asthma patients when compared to healthy
individuals.
The immune response to bacterial antigens also involves
the production of cytokines, which may be biased in asthma
patients by their underlying condition. TNF-a is a proin-
flammatory cytokine that is considered to be responsible for
several aspects of the airway pathology in asthma. In our
experimental system we evaluated the cytokine production
capacity of PBMC by non-specific stimulation and flow
cytometry. A significantly lower percentage of TNF-a and a
marked tendency towards a lower percentage of IFN-g-
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expressing cells was observed in asthma patients compared
to healthy individuals. These results are partially in accord-
ance with those of Machura et al., which describe a decrease
in IFN-g production, evaluated by intracellular cytokine
staining in T cells from asthma patients compared to
healthy subjects, while TNF-a was similar in both groups
[36]. Several clinical trials have evaluated biological thera-
pies that target inflammatory mediators such as TNF-a.
This cytokine, considered initially as a product of macro-
phages, can be expressed by a broad range of cell types [37],
so it is possible that the elevated levels reported by others
are derived from cells other than those we evaluated, or are
generated at local sites.
In our data, levels of IFN-g in serum were lower in asth-
matics with respect to the control group. However, in
non-stimulated supernatants from cultured PBMC, high
production was detected in the cells from asthma patients
under exacerbation. This may be due to an in-vivo partial
stimulation related to the exacerbation state, which results
during the culture in the production of this cytokine. A sig-
nificantly higher percentage of cells expressing IL-5, a
typical Th2 cytokine, was observed in these patients, but no
differences could be observed for IL-4 and IL-13, hallmarks
of asthma and other allergic conditions. This is in agree-
ment with the results of Kuo et al., who reported signifi-
cantly higher IL-5 and lower IFN-g production from
activated PBMC of asthmatic patients than of normal
controls [38].
The specific response to the bacterial antigens was also
evaluated by the concentration of cytokines in supernatants
of cultured cells. Higher levels of IFN-g, our marker of Th1
cytokine production, were observed under exacerbation in
the non-stimulated samples. IFN-g production has also
been reported in response to Spn [39]. Lama et al. have
reported that serum levels of IFN-g were significantly lower
in both steroid-naive and steroid-treated groups of asth-
matic children compared to healthy control subjects, but
they do not make reference to exacerbation [40].
The cytokine evaluated for Th2 cells was IL-5. A tendency
to lower values was observed in the exacerbation condition
in response to the bacterial antigens when compared to the
stable condition, although the response to Mtb was always
higher than to Spn. Robroeks et al. have proposed IL-5
levels in exhaled breath as a significant predictor of asthma
exacerbations [41]. It is possible, then, that the IL-5 in-vitro
production by antigen-stimulated PBMC is reduced in
asthma patients under exacerbation because these cells have
exhausted their capacity in vivo, explaining the tendency
observed in our data. This may also be due to the fact that
in the presence of Spn, an immune response is elicited that
may counteract or interact with the ongoing Th2 response
present in asthma through other mediators.
Asthma has been related to defects in the regulation of
the immune response, and IL-10 is a regulatory cytokine
involved in the physiopathology of this disease. We evalu-
ated the production of this cytokine in our experimental
model. IL-10 production was greatly stimulated by both
Spn and Mtb when compared to non-stimulated cultured
cells, with similar levels to both bacterial stimuli and in
both patient conditions.
A recent study on the immune response elicited by heat-
killed and live pneumococci in human cells reports that the
former triggered a Th1-biased response while the latter trig-
gered a Th17 response [16]. Therefore, our experimental
data provide useful information but cannot be extrapolated
directly to the pathophysiological in-vivo situation. Impor-
tant differences have been reported for cells from the
periphery and cells from the local environment, in our case
the lung. Several studies in HIV infection have reported
increased numbers of Treg cells in local tissue, while the per-
centage of these cells in the peripheral blood remained
similar to that of healthy individuals [42]. This may be also
the case in our experiments, but we had no access to
broncheoalveolar lavage or patient sputum. Cho et al. have
also published that findings in blood did not reflect those in
the airways [43]. It is possible that more differences could
be observed with those sample types. Further studies on
these materials might provide a clearer insight into the
immune response to S. pneumoniae in asthma patients.
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